Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The Company Will Begin Hiring A Sales Force

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Team building
Bristol is laying the foundation for a new launch • Source: Alamy

Bristol Myers Squibb Company is already laying the commercial groundwork for the launch of its potential first-in-class TYK2 inhibitor deucravacitinib for psoriasis even though a US approval is at least a year away. The company said it will begin hiring a sales force in the second half of the year as it plans to make a blockbuster-sized splash into a new therapy area dominated by experienced rivals. The company has already established a medical team experienced in dermatology.

"This is a new area for BMS, and thus we've been engaged in a significant capability build to ensure that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category